First Synthesis of 3-Amino-2-arylimidazo[1,2-b]pyridazines by Groebke-Blackburn
Reaction

Clemens Lamberth

doi:10.1055/s-0030-1260940

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Synlett 2011(12): 1740-1744
DOI: 10.1055/s-0030-1260940

LETTER

First Synthesis of 3-Amino-2-arylimidazo[1,2-b]pyridazines by Groebke-Blackburn Reaction

Clemens Lamberth*
Syngenta Crop Protection AG, Research Chemistry, Schaffhauserstr. 101, 4332 Stein, Switzerland
Fax: +41(62)8660860; e-Mail: clemens.lamberth@syngenta.com;

Further Information

Publication History

Received 1 April 2011
Publication Date:
05 July 2011 (online)

Abstract
Full Text
References

Permissions and Reprints All articles of this category

Abstract

The Groebke-Blackburn transformation of an 3-aminopyridazine, a benzaldehyde, and an isocyanide allows the one-step assembly of so far unknown 3-amino-2-arylimidazo[1,2-b]-pyridazines. Diversely substituted aldehydes and isocyanides can be used for this reliable three-component condensation, delivering biheterocyclic products with a broad range of different substituents in the imidazole moiety.

Key words

multicomponent reaction - Groebke-Blackburn reaction - heterocycles - imidazopyridazines - ring closure

References and Notes

1a Dömling A. Chem. Rev. 2006, 106: 17

Google Scholar
1b Multicomponent Reactions Zhu J. Bienayme H. Wiley-VCH; Weinheim: 2005.

Google Scholar
2a Synthesis of Heterocycles via Multicomponent Reactions, In Top. Heterocycl. Chem. Orru R. V. A., Ruijter E. Vol. 23: Springer; Berlin: 2010.

Google Scholar
2b Jiang B. Shi F. Tu S.-J. Curr. Org. Chem. 2010, 14: 357

Google Scholar
2c Jiang B. Rajale T. Wever W. Tu S.-J. Li G. Chem. Asian J. 2010, 5: 2318

Google Scholar
2d Ivachtchenko AV. Ivanenkov YA. Kysil VM. Krasavin MY. Ilyin AP. Russ. Chem. Rev. 2010, 79: 787

Google Scholar
2e Sunderhaus JD. Martin SF. Chem. Eur. J. 2009, 15: 1300

Google Scholar
2f D’Souza DM. Müller TJJ. Chem. Soc. Rev. 2007, 36: 1095

Google Scholar
3a Groebke K. Weber L. Mehlin F. Synlett 1998, 661

Google Scholar
3b Blackburn C. Guan B. Fleming P. Shiosaki K. Tsai S. Tetrahedron Lett. 1998, 39: 3635

Google Scholar
3c Bienayme H. Bouzid K. Angew. Chem. Int. Ed. 1998, 37: 2234 ; Angew. Chem. 1998, 110, 2349

Google Scholar
4a Li L. Hopkinson MN. Yona RL. Bejot R. Gee AD. Gouverneur V. Chem. Sci. 2011, 2: 123

Google Scholar
4b Odell LR. Nilsson MT. Gising J. Lagerlund O. Muthas D. Nordqvist A. Karlen A. Larhed M. Bioorg. Med. Chem. Lett. 2009, 19: 4790

Google Scholar
4c Lacerda RB. de Lima CKF. da Silva LL. Romeiro NC. Miranda ALP. Barreiro EJ. Fraga CAM. Bioorg. Med. Chem. 2009, 17: 74

Google Scholar
4d Shaabani A. Soleimani E. Sarvary A. Rezayan AH. Maleki A. Chin. J. Chem. 2009, 27: 369

Google Scholar
4e Rousseau AL. Matlaba P. Parkinson CJ. Tetrahedron Lett. 2007, 48: 4079

Google Scholar
4f Shaabani A. Maleki A. Rad JM. Soleimani E. Chem. Pharm. Bull. 2007, 55: 957

Google Scholar
4g Shaabani A. Soleimani E. Maleki A. Tetrahedron Lett. 2006, 47: 3031

Google Scholar
4h Chen JJ. Golebiowski A. McClenaghan J. Klopfenstein SR. West L. Tetrahedron Lett. 2001, 42: 2269

Google Scholar
5a Shaabani A. Rezazadeh F. Soleimani E. Monatsh. Chem. 2008, 139: 931

Google Scholar
5b Shaabani A. Soleimani E. Maleki A. Moghimi-Rad J. Synth. Commun. 2008, 38: 1090

Google Scholar
5c Sandulenko Y. Komarov A. Rufanov K. Krasavin M. Tetrahedron Lett. 2008, 49: 5990

Google Scholar
5d Varma RS. Kumar D. Tetrahedron Lett. 1999, 40: 7665

Google Scholar
5e Blackburn C. Tetrahedron Lett. 1998, 39: 5469

Google Scholar
6 Al-Tel TH. Al-Qawasmeh RA. Voelter W. Eur. J. Org. Chem. 2010, 5586

Google Scholar
7 Krasavin M. Tsirulnikov S. Nikulnikov M. Sandulenko Y. Bukhryakov K. Tetrahedron Lett. 2008, 49: 7318

Crossref Google Scholar
8 Guchhait SK. Maadan C. Synlett 2009, 628

Article in Thieme Connect Google Scholar
9 Guchhait SK. Maadan C. Thakkar BS. Synthesis 2009, 3293

Article in Thieme Connect Google Scholar
10a Guchhait SK. Madaan C. Org. Biomol. Chem. 2010, 8: 3631

Google Scholar
10b Ireland SM. Tye H. Whittaker M. Tetrahedron Lett. 2003, 44: 4369

Google Scholar
11 Polyakov AI. Eryomina VA. Medvedeva LA. Tihonova NI. Voskressensky LG. J. Heterocycl. Chem. 2008, 45: 1589

Crossref Google Scholar
12 Krasavin M. Tsirulnikov S. Nikulnikov M. Kysil V. Ivachtchenko A. Tetrahedron Lett. 2008, 49: 5241

Crossref Google Scholar
13 Parchinsky VZ. Koleda VV. Shuvalova O. Kravchenko DV. Krasavin M. Tetrahedron Lett. 2006, 47: 6891

Crossref Google Scholar
14 Tsirulnikov S. Kysil V. Ivachtchenko A. Krasavin M. Synth. Commun. 2010, 40: 111

Google Scholar
15a Zhou T. Commodore L. Huang W.-S. Wang Y. Thomas M. Keats J. Xu Q. Rivera VM. Shakespeare WC. Clackson T. Dalgarno DC. Zhu X. Chem. Biol. Drug Des. 2011, 77: 1

Google Scholar
15b Huang W.-S. Metcalf CA. Sundaramoorthi R. Wang Y. Zou D. Thomas RM. Zhu X. Cai L. Wen D. Liu S. Romero J. Qi J. Chen I. Banda G. Lentini SP. Das S. Xu Q. Keats J. Wang F. Wardwell S. Ning Y. Snodgrass JT. Broudy MI. Russian K. Zhou T. Commodore L. Narasimhan NI. Mohemmad QK. Iuliucci J. Rivera VM. Dalgarno DC. Sawyer TK. Clackson T. Shakespeare WC. J. Med. Chem. 2010, 53: 4701

Google Scholar
16a Fukuda S. Midoro K. Yamasaki M. Gyoten M. Kawano Y. Fukui H. Ashida Y. Nagaya H. Inflammation Res. 2003, 52: 206

Google Scholar
16b Fukuda S. Midoro K. Kamei T. Gyoten M. Kawano Y. Ashida Y. Nagaya H. J. Pharmacol. Exp. Ther. 2002, 303: 1283

Google Scholar
17 Bouloc N. Large JM. Smiljanic E. Whalley D. Ansell KH. Edlin CD. Bryans JS. Bioorg. Med. Chem. Lett. 2008, 18: 5294

Crossref Google Scholar
18 Hamdouchi C. Sanchez-Martinez C. Gruber J. del Prado M. Lopez J. Rubio A. Heinz BA. J. Med. Chem. 2003, 46: 4333

Crossref Google Scholar
19 Russell MGN. Carling RW. Street LJ. Hallett DJ. Goodacre S. Mezzogori E. Reader M. Cook SM. Bromidge FA. Newman R. Smith AJ. Wafford KA. Marshall GR. Reynolds DS. Dias R. Ferris P. Stanley J. Lincoln R. Tye SJ. Sheppard WFA. Sohal B. Pike A. Dominguez M. Atack JR. Castro JL. J. Med. Chem. 2006, 49: 1235

Crossref Google Scholar
20 Zeng F. Alagille D. Tamagnan GD. Ciliax BJ. Levey AI. Goodman MM. ACS Med. Chem. Lett. 2010, 1: 80

Crossref Google Scholar
21a Lamberth C. Jeanguenat A. Cederbaum F. De Mesmaeker A. Zeller M. Kempf H.-J. Zeun R. Bioorg. Med. Chem. 2008, 16: 1531

Google Scholar
21b Lamberth C. Kempf H.-J. Kriz M. Pest Manag. Sci. 2007, 63: 57

Google Scholar
21c Lamberth C. Cederbaum F. Jeanguenat A. Kempf H.-J. Zeller M. Zeun R. Pest Manag. Sci. 2006, 62: 446

Google Scholar
21d Cederbaum F. De Mesmaeker A. Jeanguenat A. Kempf H.-J. Lamberth C. Schnyder A. Zeller M. Zeun R. Chimia 2003, 57: 680

Google Scholar
23a Fayol A. Zhu J. Org. Lett. 2004, 6: 115

Google Scholar
23b Fayol A. Zhu J. Angew. Chem. Int. Ed. 2002, 41: 3633 ; Angew. Chem. 2002, 114, 3785

Google Scholar
23c Janvier P. Sun X. Bienayme H. Zhu J. J. Am. Chem. Soc. 2002, 124: 2560

Google Scholar

22

Representative Procedure
tert-Butyl isocyanide (4a, 200 mg, 2.4 mmol), benzaldehyde (5a, 233 mg, 2.2 mmol), and 3-amino-6-chloropyridazine (3, 260 mg, 2.0 mmo) are consecutively added to a solution of NH₄Cl (107 mg, 2.0 mmol) in MeOH (10 mL). The reaction mixture is stirred for 16 h at r.t. Subsequently, the solvent was removed in vacuo and the remainder taken up in EtOAc. This organic layer was washed with brine and H₂O, dried over Na₂SO₄ and evaporated. The residue was purified either by crystallization from Et₂O or by chromatography on silica gel, using cyclohexane-EtOAc (4:1) as eluent to deliver
3-tert-butylamino-6-chloro-2-phenylimidazo[1,2-b]pyrida-zine as yellow crystals (6a, 500 mg, 1.7 mmol, 83%); mp 219-222 ˚C. ^¹H NMR (400 MHz, CDCl₃): δ = 1.13 (s, 9 H), 3.44 (br s, 1 H), 6.95 (d, 1 H), 7.32 (t, 1 H), 7.43 (t, 2 H), 7.80 (d, 1 H), 8.22 (d, 2 H) ppm. LC-MS: t _R = 1.93 min, m/z = 301 [M + 1].

24

Further Spectroscopic Data Compound 6b: ^¹H NMR (400 MHz, CDCl₃): δ = 0.89 (t, 3 H), 1.38 (q, 2 H), 1.57 (q, 2 H), 3.15 (q, 2 H), 3.99 (t, 1 H), 6.85 (d, 1 H), 7.32 (t, 1 H), 7.44 (t, 2 H), 7.78 (d, 1 H), 8.03 (d, 2 H) ppm. LC-MS: t _R = 2.05 min, m/z = 301 [M + 1].
Compound 6c: ^¹H NMR (400 MHz, CDCl₃): δ = 1.12-1.89 (m, 10 H), 3.22 (q, 1 H), 3.89 (d, 1 H), 6.87 (d, 1 H), 7.32 (t, 1 H), 7.44 (t, 2 H), 7.78 (d, 1 H), 8.10 (d, 2 H) ppm. LC-MS: t _R = 2.15 min, m/z = 327 [M + 1].
Compound 6d: ^¹H NMR (400 MHz, CDCl₃): δ = 1.11 (s, 6 H), 2.20 (s, 3 H), 2.73 (s, 2 H), 3.96 (br s, 1 H), 6.96 (d, 1 H), 7.33 (t, 1 H), 7.42 (t, 2 H), 7.80 (d, 1 H), 8.21 (d, 2 H) ppm. LC-MS: t _R = 2.04 min, m/z = 347 [M + 1].
Compound 6e: ^¹H NMR (400 MHz, CDCl₃): δ = 1.03 (s, 6 H), 1.10 (s, 9 H), 1.18 (s, 2 H), 3.56 (br s, 1 H), 6.91 (d, 1 H), 7.31 (t, 1 H), 7.42 (t, 2 H), 7.78 (d, 1 H), 8.17 (d, 2 H) ppm. LC-MS: t _R = 2.32 min, m/z = 357 [M + 1].
Compound 6f: ^¹H NMR (400 MHz, CDCl₃): δ = 5.88 (br s, 1 H), 6.55 (d, 1 H), 6.64 (s, 1 H), 6.72-6.79 (m, 2 H), 7.05 (d, 1 H), 7.29-7.56 (m, 4 H), 7.91 (d, 1 H), 8.10 (d, 2 H) ppm. LC-MS: t _R = 1.89 min, m/z = 361 [M + 1].
Compound 6g: ^¹H NMR (400 MHz, CDCl₃): δ = 2.01 (s, 6 H), 5.69 (br s, 1 H), 6.81-6.93 (m, 4 H), 7.14-7.20 (m, 3 H), 7.58 (dd, 2 H), 7.82 (d, 1 H) ppm. LC-MS: t _R = 2.03 min, m/z = 349 [M + 1].
Compound 6h: ^¹H NMR (400 MHz, CDCl₃): δ = 4.30-4.39 (m, 3 H), 6.87 (d, 1 H), 7.19-7.36 (m, 6 H), 7.47 (t, 2 H), 7.78 (d, 1 H), 8.01 (d, 2 H) ppm. LC-MS: t _R = 1.98 min, m/z = 335 [M + 1].
Compound 6i: ^¹H NMR (400 MHz, CDCl₃): δ = 1.11 (s, 9 H), 3.46 (br s, 1 H), 6.99 (d, 1 H), 7.52-7.83 (m, 4 H), 8.47 (d, 1 H), 8.66 (d, 1 H) ppm. LC-MS: t _R = 2.19 min, m/z = 369 [M + 1].
Compound 6j: ^¹H NMR (400 MHz, CDCl₃): δ = 1.12 (s, 9 H), 3.43 (br s, 1 H), 6.97 (d, 1 H), 7.21-7.28 (m, 2 H), 7.80 (d, 1 H), 8.30 (d, 2 H) ppm. LC-MS: t _R = 2.20 min, m/z = 385 [M + 1].
Compound 6k: ^¹H NMR (400 MHz, CDCl₃): δ = 1.13 (s, 9 H), 2.31 (s, 3 H), 3.40 (br s, 1 H), 6.95 (d, 1 H), 7.22 (t, 1 H), 7.79 (d, 1 H), 7.92-7.98 (m, 2 H) ppm. LC-MS: t _R = 2.14 min, m/z = 333 [M + 1].
Compound 6l: ^¹H NMR (400 MHz, CDCl₃): δ = 1.16 (s, 9 H), 3.42 (br s, 1 H), 6.98 (d, 1 H), 7.43 (t, 1 H), 7.80 (d, 1 H), 8.03 (d, 1 H), 8.15 (d, 1 H) ppm. LC-MS: t _R = 2.23 min,
m/z = 353 [M + 1].
Compound 6m: ^¹H NMR (400 MHz, CDCl₃): δ = 1.04 (s, 9 H), 3.58 (br s, 1 H), 3.95 (s, 3 H), 6.88-7.04 (m, 2 H), 7.20 (t, 1 H), 7.39 (t, 1 H), 7.82 (d, 1 H) ppm. LC-MS: t _R = 1.92 min, m/z = 349 [M + 1].
Compound 6n: ^¹H NMR (400 MHz, CDCl₃): δ = 1.07 (s, 9 H), 3.58 (br s, 1 H), 3.96 (s, 3 H), 7.00 (d, 1 H), 7.27 (s, 1 H), 7.48 (d, 1 H), 7.83 (d, 1 H) ppm. LC-MS: t _R = 2.07 min, m/z = 383 [M + 1].
Compound 6o: ^¹H NMR (400 MHz, CDCl₃): δ = 1.04 (s, 9 H), 3.49 (br s, 1 H), 6.03 (s, 2 H), 6.95-7.00 (m, 2 H), 7.06 (s, 1 H), 7.81 (d, 1 H) ppm. LC-MS: t _R = 1.98 min, m/z = 379 [M + 1].
Compound 7: ^¹H NMR (400 MHz, CDCl₃): δ = 1.12 (s, 9 H), 3.33 (br s, 1 H), 3.48 (s, 3 H), 3.80 (t, 2 H), 4.49 (t, 2 H), 6.63 (d, 1 H), 7.28 (t, 1 H), 7.41 (t, 2 H), 7.72 (d, 1 H), 8.23 (d, 2 H) ppm. LC-MS: t _R = 1.58 min, m/z = 341 [M + 1].
Compound 8: ^¹H NMR (400 MHz, CDCl₃): δ = 3.75 (br s, 1 H), 7,11 (dd, 1 H), 6.95 (d, 1 H), 7.33 (t, 1 H), 7.45 (t, 2 H), 7.82-7.88 (m, 2 H), 7.97 (d, 1 H), 8.22 (d, 2 H) ppm.
LC-MS: t _R = 1.89 min, m/z = 355 [M + 1].
Compound 9: ^¹H NMR (400 MHz, CDCl₃): δ = 1.15 (s, 9 H), 3.45 (t, 4 H), 3.72 (t, 4 H), 3.51 (br s, 1 H), 6.89 (d, 1 H), 7.31 (t, 1 H), 7.43 (t, 2 H), 7.82 (d, 1 H), 8.26 (d, 2 H) ppm.
LC-MS: t _R = 1.77 min, m/z = 352 [M + 1].
Compound 10: ^¹H NMR (400 MHz, CDCl₃): δ = 4.41 (br s, 2 H), 6.83 (t, 1 H), 7.32 (t, 1 H), 7.40-7.52 (m, 2 H), 7.76 (t, 1 H), 7.92 (t, 2 H) ppm. LC-MS: t _R = 1.46 min, m/z = 245
[M + 1].
Compound 11: ^¹H NMR (400 MHz, CDCl₃): δ = 1.12 (s, 9 H), 3.56 (br s, 1 H), 3.77 (s, 6 H), 5.80 (s, 1 H), 7.31 (t, 2 H), 7.44 (t, 2 H), 7.82 (d, 1 H), 8.29 (d, 2 H) ppm. LC-MS: t _R = 2.12 min, m/z = 437 [M + 1].
Compound 12: ^¹H NMR (400 MHz, CDCl₃): δ = 1.18 (t, 3 H), 2.74 (q, 2 H), 3.56 (br s, 1 H), 6.97 (d, 1 H), 7.33 (t, 1 H), 7.40-7.48 (m, 2 H), 7.80 (d, 1 H), 8.30 (d, 2 H) ppm.
LC-MS: t _R = 1.67 min, m/z = 337 [M + 1].